Clinical Trial Update: A Study to Evaluate Food Effect on ONO-5920/YM529 Intermittent Formulation [Phase 1]

View source ↗

Summary

This is a Phase 1 study evaluating the effect of food on the intermittent formulation of ONO-5920/YM529 for osteoporosis. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• ONO-5920
• YM529

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Osteoporosis, Osteoporosis, Postmenopausal | Phase 1 | Status: COMPLETED